PanGenetics

About PanGenetics

PanGenetics BV operated as a clinical-stage biotechnology company with a strategic focus on developing therapeutic antibodies for chronic inflammation and pain. Headquartered in Utrecht, The Netherlands, with an additional office in Cambridge, UK, the company employed a lean, asset-centric business model. This approach involved outsourcing most of its development activities, including manufacturing and clinical trials, to specialized providers, allowing it to advance antibody candidates from late-stage research to clinical proof of concept efficiently.

The company was led by CEO Kevin Johnson, who brought extensive experience from his time as CTO at Cambridge Antibody Technology. A significant milestone for PanGenetics occurred in November 2009 when it sold the global rights for its lead product, PG110, to the pharmaceutical firm Abbott. This deal, valued at up to $190 million with a $170 million upfront payment, represented a major achievement and provided a substantial return for its investors. Following this transaction, PanGenetics' other primary asset, PG102, was spun out to form a new entity called Fast Forward Pharma.

PanGenetics' primary offerings were its antibody pipeline candidates. PG110 was a humanized antibody designed to target Nerve Growth Factor (NGF), playing a key role in treating chronic pain, particularly from conditions like osteoarthritis. The antibody works by binding to NGF and preventing its interaction with nerve receptors, which is a crucial mechanism in pain signaling. The other key program was PG102, a CD40 antagonist aimed at treating various autoimmune diseases, which had been evaluated in clinical studies for conditions such as psoriatic arthritis and Crohn's disease. The company's business model was centered on advancing these high-potential antibody assets through the clinical development process to a point where they became attractive acquisition targets for large pharmaceutical companies, as demonstrated by the Abbott deal.

The company's journey was supported by significant venture capital funding. In March 2008, it secured €23 million in a Series C financing round led by Edmond de Rothschild Investment Partners and included participation from notable investors like Index Ventures, Forbion Capital Partners, and Biogen Idec New Ventures. This capital was crucial for advancing the clinical trials of both PG102 and PG110. The successful development and subsequent sale of its primary asset validated the company's strategy of focusing on the clinical advancement of promising antibodies without maintaining extensive in-house research operations.